{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-104567","form_type":"8-K","ticker":"HOTH","cik":"0001711786","company_name":"Hoth Therapeutics, Inc.","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.311717+00:00","generated_at":"2026-05-29T11:26:36.546144+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Hoth Therapeutics releases December 2024 corporate presentation highlighting pipeline and milestones","bullets":["HT-001 Phase 2a for EGFR inhibitor skin toxicity: all sites active, enrolling open-label and double-blind; interim PK data expected Q1 2025.","HT-KIT: pre-IND meeting with FDA successful; IND-enabling tox studies ongoing; IND submission target Q4 2025.","HT-ALZ: US patent awarded Q3 2024; preclinical studies completed at WashU; pre-IND meeting planned for 2025.","BioLexa Phase 1b data readout completed in 2023; proof-of-concept results shown; non-corticosteroid treatment for atopic dermatitis.","7.7M shares outstanding as of Nov 29, 2024; cash on hand sufficient to fund current clinical and preclinical programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-104567","json":"https://secwatch.observer/filing/0001213900-24-104567.json","markdown":"https://secwatch.observer/filing/0001213900-24-104567.md","text":"https://secwatch.observer/filing/0001213900-24-104567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711786/000121390024104567/0001213900-24-104567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711786/000121390024104567/ea0223333-8k_hoth.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T11:26:36.546144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}